Anxiety disorders: use of benzodiazepines


DOI: https://dx.doi.org/10.18565/pharmateca.2025.4.96-101

Kotova O.V., Akarachkova E.S., Belyaeva A.A., Lebedeva D.I.

1) Faculty of Continuous Medical Education, Medical Institute, People’s Friendship University of Russia (RUDN University), Moscow, Russia; 2) International Society “Stress under Control”, Moscow, Russia; 3) Rehaline Rehabilitation Center, Krasnogorsk, Russia; 4) Regional Treatment and Rehabilitation Center, Tyumen, Russia; 5) Tyumen State Medical University, Tyumen, Russia
Anxiety disorders are the most common type of mental illness. Due to their high prevalence (3.3% of the global disease burden), chronic course and a large number of comorbidities, anxiety disorders are among the nine leading causes of disability. The presence of anxiety in heart disease, cancer or lung disease negatively affects the quality of life, treatment adherence, prognosis and treatment costs. Anxiety disorders are treated using psychotherapy, pharmacotherapy or a combination of both. Benzodiazepines are an effective treatment for anxiety, if prescribed as directed and with control over adverse events, some of which are described in the article. Unlike SSRIs, which are first-line drugs for treating anxiety disorders, the anxiolytic effect of which develops only after 2–4 weeks of use, benzodiazepines provide a rapid pharmacological response with reduction of anxiety symptoms within a short time. In this regard, their use is advisable in short courses for rapid symptom relief. Diamidazepam, a member of the benzodiazepine group, combines a powerful anti-anxiety effect with an activating and anti-asthenic effect, while being virtually devoid of the side effects of classic benzodiazepines in the form of excessive sedation, drowsiness, and muscle relaxation.
Keywords: diamidazepam, adverse effects of benzodiazepines, benzodiazepines, anxiety disorders
Read entire article

About the Autors

Olga V. Kotova, Cand. Sci. (Med.), Neurologist, Psychiatrist, Associate Professor at the Department of Psychiatry, Psychotherapy and Psychosomatic Pathology, Faculty of Continuous Medical Education, Medical Institute, People’s Friendship University of Russia (RUDN University); Vice-President of the International Society “Stress Under Control”, Moscow, Russia; ol_kotova@mail.ru, ORCID: https://orcid.org/0000-0002-3908-0381 (corresponding author)
Elena S. Akarachkova, Dr. Sci. (Med.), Neurologist, President of the International Society “Stress Under Control” (Moscow), Deputy Chief Physician of the Rehaline Rehabilitation Center, Krasnogorsk, Russia; ORCID: https://orcid.org/0000-0002-7629-3773
Aleksandra A. Belyaeva, Student, Medical Institute, People’s Friendship University of Russia (RUDN University), Moscow, Russia; ORCID:
https://orcid.org/0009-0002-1047-7788
Dzhinna I. Lebedeva, Dr. Sci. (Med.), neurologist, Honored Doctor of the Russian Federation, Chief Physician, Regional Treatment and Rehabilitation Center; Associate Professor of the Department of Medical Prevention and Rehabilitation, Institute of Public Health and Digital Medicine, Tyumen State Medical University, Tyumen, Russia


Similar Articles

Back to Content

Бионика Медиа